Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants

Core Viewpoint - Outlook Therapeutics, Inc. has initiated an underwritten public offering of its common stock and accompanying warrants, aimed at enhancing the standard of care for bevacizumab in treating retina diseases [1][2] Group 1: Offering Details - The offering is subject to market conditions, and there is no assurance regarding its completion or the actual size and terms [1] - The net proceeds from the offering will be utilized for working capital and other general corporate purposes [2] - BTIG, LLC is serving as the sole book-running manager for the offering [2] Group 2: Regulatory and Product Information - The securities are being offered under a shelf registration statement declared effective by the SEC on April 5, 2024 [3] - Outlook Therapeutics is focused on the development of ONS-5010/LYTENAVA™ (bevacizumab-vikg), which is the first ophthalmic formulation of bevacizumab approved for wet age-related macular degeneration in the EU and UK [5] - The company plans to initiate the commercial launch of LYTENAVA™ in the EU and UK in the second quarter of 2025, while the product is still investigational in the U.S. [5]